Sugi Predict

Sugi Predict / Compounds / SCHEMBL3701267

SCHEMBL3701267

SCHEMBL3701267

Cc1cccc(-c2ccc(C[C@H](NC(=O)C3(CC(=O)O)CCCC3)c3nnn[nH]3)cc2)c1

nearest known ligand 0.43

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ MME P08473 1/20 0.43
▸ ITGB1 P05556 9/20 0.39
▸ ITGA4 P13612 9/20 0.39
▸ KMT2A Q03164 1/20 0.38
▸ ITGB7 P26010 1/20 0.38
▸ PPARG P37231 1/20 0.37
▸ PPARA Q07869 1/20 0.37
▸ MMEL1 Q495T6 2/20 0.37
▸ CCNA2 P20248 1/20 0.36
▸ CDK2 P24941 1/20 0.36
▸ CCNA1 P78396 1/20 0.36
▸ MMP1 P03956 1/20 0.36
▸ DGAT1 O75907 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3696881 1.00 MME (0.43) MMEITGB1ITGA4KMT2AITGB7
SCHEMBL3707948 0.91 ITGB1 (0.43) MMEITGB1ITGA4MMEL1MMP1
SCHEMBL6125680 0.90 MMEL1 (0.48) MMEMMEL1
SCHEMBL3699639 0.90 MMEL1 (0.48) MMEMMEL1
SCHEMBL7507623 0.89 MME (0.45) MMEITGB1ITGA4ITGB7MMP1
SCHEMBL7507651 0.89 PPARG (0.39) MMEITGB1ITGA4ITGB7PPARG
SCHEMBL16214799 0.83 ITGB1 (0.39) MMEITGB1ITGA4MMEL1MMP1
SCHEMBL7508372 0.79 ITGB1 (0.40) MMEITGB1ITGA4MMP1
SCHEMBL7513252 0.79 GPR34 (0.42) MMEKMT2AMMEL1CDK2
SCHEMBL3696891 0.77 KMT2A (0.34) MMEKMT2APPARGPPARACCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8877815-B2 Substituted carbamoylcycloalkyl acetic acid derivatives as NEP NOVARTIS AG (CH) 2014-11-04 — — US disclosed
US-8877815-B2 Substituted carbamoylcycloalkyl acetic acid derivatives as NEP NOVARTIS AG (CH) 2014-11-04 — — US disclosed
US-8877815-B2 Substituted carbamoylcycloalkyl acetic acid derivatives as NEP NOVARTIS AG (CH) 2014-11-04 — — US disclosed
EP-2640689-A1 SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP INHIBITORS Novartis AG (CH) 2013-09-25 — — EP disclosed
WO-2012065953-A1 SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP INHIBITORS NOVARTIS AG (CH) 2012-05-24 — — WO disclosed
US-20120122764-A1 SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP NOVARTIS AG (CH) 2012-05-17 — — US disclosed
US-20120122764-A1 SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP NOVARTIS AG (CH) 2012-05-17 — — US disclosed
US-20120122764-A1 SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP NOVARTIS AG (CH) 2012-05-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122764-A1 SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP MME, REN, ECE1 MME 1/4885ITGB1 4710/4885ITGA4 4568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.